New study tracks how well nintedanib works over time for scleroderma lung disease
NCT ID NCT07080125
First seen Dec 08, 2025 · Last updated Jun 22, 2026 · Updated 24 times
Summary
This study follows 2,000 people with systemic sclerosis (scleroderma) who have lung disease and are taking the drug nintedanib (Ofev®). Researchers want to see how the drug affects lung function, quality of life, and survival over the long term. The study is observational, meaning it just watches what happens in real-world care, without giving anyone a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
EUSTAR Registry
Basel, 4051, Switzerland
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nintedanib (Ofev®)
What this could lead to
If successful, this study could confirm that nintedanib helps slow lung decline and improve survival in people with systemic sclerosis-associated lung disease.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. It also only includes patients already enrolled in a registry, which may limit how well findings apply to everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.